中国肿瘤生物治疗杂志2026，Vol.33Issue(8)：811-821,11.DOI:10.3872/j.issn.1007-385X.2026.08.001
从计数到分型:纳米多肽CTC检测技术赋能肿瘤精准生物治疗
From enumeration to molecular subtyping:nanopeptide-based circulating tumor cell(CTC)detection for precision cancer biotherapy
摘要
Abstract
Circulating tumor cells(CTCs),regarded as the"seed cells"of tumor metastasis,are closely associated with tumor progression,therapeutic response,and patient prognosis through changes in their abundance,molecular phenotypes,and functional states.With the development of precision oncology,CTC detection has gradually evolved from simple enumeration toward molecular subtyping and therapeutic decision support.In recent years,nanopeptide-based CTC enrichment and subtyping platforms have emerged as promising liquid biopsy technologies.By integrating peptide-functionalized magnetic nanobead-mediated enrichment with multidimensional molecular profiling,these platforms can improve the capture of rare CTCs and provide a cellular basis for therapeutic target detection,treatment monitoring,and early warning of drug resistance.The nanopeptide-based CTC detection technology developed by the National Center for Nanoscience and Technology,China(NCNST)has established a clinically accessible detection system with high sensitivity and specificity,promoting the transition of CTC detection from"quantitative assessment"to a 2.0 era centered on molecular subtyping and treatment decision support.This review focuses on the core principles,key technological breakthroughs,and clinical translational value of nanopeptide-based CTC detection platforms in precision cancer biotherapy,and discusses the challenges related to standardization,cost control,level of clinical evidence,and translation into companion diagnostics,to provide a reference for optimizing precision biotherapeutic strategies in oncology.关键词
循环肿瘤细胞/液体活检/纳米多肽/分子分型/肿瘤精准生物治疗Key words
circulating tumor cell(CTC)/liquid biopsy/nanopeptide/molecular subtyping/precision cancer biotherapy分类
医药卫生引用本文复制引用
马天一,胡志远..从计数到分型:纳米多肽CTC检测技术赋能肿瘤精准生物治疗[J].中国肿瘤生物治疗杂志,2026,33(8):811-821,11.基金项目
国家重点研发计划(2023YFC2507000) （2023YFC2507000）
国家自然科学基金(32471456) （32471456）
